Share on StockTwits

PDL BioPharma (NASDAQ:PDLI) issued its quarterly earnings data on Monday. The company reported $0.52 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.46 by $0.06, AmericanBankingNews.com reports. The company had revenue of $162.80 million for the quarter, compared to the consensus estimate of $134.07 million. During the same quarter in the prior year, the company posted $0.62 earnings per share. The company’s quarterly revenue was up 9.6% on a year-over-year basis.

Shares of PDL BioPharma (NASDAQ:PDLI) traded down 1.58% during mid-day trading on Monday, hitting $9.32. The stock had a trading volume of 3,727,093 shares. PDL BioPharma has a 1-year low of $7.38 and a 1-year high of $10.21. The stock has a 50-day moving average of $9.46 and a 200-day moving average of $8.89. The company has a market cap of $1.497 billion and a P/E ratio of 5.45.

PDL BioPharma, Inc (NASDAQ:PDLI) is a is a biotech company.

Receive News & Ratings for PDL BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.